MX2022011291A - New recombinant lysin and its use in the treatment of gram-negative bacterial infections. - Google Patents

New recombinant lysin and its use in the treatment of gram-negative bacterial infections.

Info

Publication number
MX2022011291A
MX2022011291A MX2022011291A MX2022011291A MX2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A
Authority
MX
Mexico
Prior art keywords
gram
treatment
new
bacterial infections
negative bacterial
Prior art date
Application number
MX2022011291A
Other languages
Spanish (es)
Inventor
Martínez Roberto Díez
Areizaga María Morales
Original Assignee
Telum Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telum Therapeutics S L filed Critical Telum Therapeutics S L
Publication of MX2022011291A publication Critical patent/MX2022011291A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New recombinant lysin and its use in the treatment of gram-negative bacterial infections The present invention relates to a new recombinant lysin and its use as antimicrobial agent in new treatment approaches for eliminating antibiotic resistant Gram-negative bacteria, and minimizing the emergence of new resistances. It further concerns polynucleotides encoding the recombinant lysin of the invention, vectors and host cells comprising the same, as well as related methods, medical uses, compositions and kits.
MX2022011291A 2020-03-11 2021-03-11 New recombinant lysin and its use in the treatment of gram-negative bacterial infections. MX2022011291A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382177 2020-03-11
EP20382254 2020-03-31
PCT/EP2021/056264 WO2021180892A1 (en) 2020-03-11 2021-03-11 New recombinant lysin and its use in the treatment of gram-negative bacterial infections

Publications (1)

Publication Number Publication Date
MX2022011291A true MX2022011291A (en) 2022-12-08

Family

ID=74859480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011291A MX2022011291A (en) 2020-03-11 2021-03-11 New recombinant lysin and its use in the treatment of gram-negative bacterial infections.

Country Status (8)

Country Link
US (1) US20230138922A1 (en)
EP (1) EP4118192A1 (en)
JP (1) JP2023517245A (en)
CN (1) CN115605587A (en)
AU (1) AU2021236351A1 (en)
CA (1) CA3175024A1 (en)
MX (1) MX2022011291A (en)
WO (1) WO2021180892A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN114774391B (en) * 2022-03-09 2023-03-14 华南农业大学 Bacteriophage lysin for resisting escherichia coli and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
KR20170024129A (en) 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 Antimicrobial agents
CN102575240B (en) 2009-08-24 2016-01-13 勒芬天主教大学，K.U.勒芬R&D new endolysin OBPgpLYS
BR112016030580B1 (en) 2014-06-26 2023-12-19 The Rockefeller University LYSINE POLYPEPTIDE AND POLYPEPTIDE FRAGMENT WITH ACTIVITY TO KILL GRAM-NEGATIVE BACTERIA
CA2998484A1 (en) 2015-09-17 2017-03-23 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
MX2019011808A (en) * 2017-04-03 2020-01-09 Sasinapas Co Ltd Engineered gram-negative endolysins.

Also Published As

Publication number Publication date
CN115605587A (en) 2023-01-13
JP2023517245A (en) 2023-04-24
WO2021180892A1 (en) 2021-09-16
AU2021236351A1 (en) 2022-10-06
US20230138922A1 (en) 2023-05-04
CA3175024A1 (en) 2021-09-16
EP4118192A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
MX2022011291A (en) New recombinant lysin and its use in the treatment of gram-negative bacterial infections.
Chessa et al. An overview of Staphylococcus epidermidis and Staphylococcus aureus with a focus on developing countries
PH12019500360A1 (en) Antibiotic compounds
BR112013003127A2 (en) bismuththiols as antiseptics for agricultural, industrial and other uses
NZ593111A (en) Antibacterial compounds
EP2046287A4 (en) Methods and compositions for the treatment and prevention of infections
CR20210682A (en) Macrocyclic broad spectrum antibiotics
JP2018509415A5 (en)
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
MX2018006199A (en) Macrocyclic broad spectrum antibiotics.
DE502005010850D1 (en) ANTIBACTERIAL AMID MACROCYCLES IV
UA87548C2 (en) Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof
MX2020012543A (en) Diltiazem for use in the treatment of microbial infections.
AR073917A1 (en) ANTIBIOTIC SYNERGISM
TW200510541A (en) Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
WO2020014501A8 (en) Compositions and methods for the treatment of bacterial infections
EP4223304A3 (en) Novel antimicrobial and anti-cancer therapy
KIM et al. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from pigs in Korea using new standardized procedures
WO2005021575A3 (en) Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties
GEP20247616B (en) Compounds and methods of use thereof as antibacterial agents
MX2022015155A (en) Formulations and methods for treating diarrhea.
IL299751A (en) Compositions and methods to disinfect, treat and prevent microbial infections
MX2021013833A (en) Methods and compositions comprising staphylococcus protein a (spa) variants.
MX2023012943A (en) Antibacterial compound.
WO2018140707A8 (en) Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces